about
Adjuvant chemotherapy for resected early-stage non-small cell lung cancerDiagnostic procedures for non-small-cell lung cancer (NSCLC): recommendations of the European Expert GroupAssociations of polymorphisms in DNA repair genes and MDR1 gene with chemotherapy response and survival of non-small cell lung cancerRegulatory challenges in the review of data from global clinical trials: the PMDA perspective.Adjuvant chemotherapy, with or without postoperative radiotherapy, in operable non-small-cell lung cancer: two meta-analyses of individual patient dataEast meets West: ethnic differences in epidemiology and clinical behaviors of lung cancer between East Asians and Caucasians.Identification of peripheral inflammatory markers between normal control and Alzheimer's disease.Survival by histologic subtype in stage IV nonsmall cell lung cancer based on data from the Surveillance, Epidemiology and End Results ProgramAdvances in adjuvant systemic therapy for non-small-cell lung cancer.A prospective, molecular epidemiology study of EGFR mutations in Asian patients with advanced non-small-cell lung cancer of adenocarcinoma histology (PIONEER)The preclinical profile of crizotinib for the treatment of non-small-cell lung cancer and other neoplastic disorders.Efficacy of everolimus with exemestane versus exemestane alone in Asian patients with HER2-negative, hormone-receptor-positive breast cancer in BOLERO-2.Differences in somatic mutation landscape of hepatocellular carcinoma in Asian American and European American populations.Clinical and epidemiological study of EGFR mutations and EML4-ALK fusion genes among Indian patients with adenocarcinoma of the lung.The clinical application of UGT1A1 pharmacogenetic testing: gene-environment interactionsEfficacy and safety of axitinib versus sorafenib in metastatic renal cell carcinoma: subgroup analysis of Japanese patients from the global randomized Phase 3 AXIS trial.Epidermal growth factor receptor mutation in adenocarcinoma lung in a North Indian population: Prevalence and relation with different clinical variables.The genetic variations in DNA repair genes ERCC2 and XRCC1 were associated with the overall survival of advanced non-small-cell lung cancer patients.Effective global drug development strategy for obtaining regulatory approval in Japan in the context of ethnicity-related drug response factors.Establishment and characterization of primary lung cancer cell lines from Chinese population.Efficacy and safety of everolimus in combination with trastuzumab and paclitaxel in Asian patients with HER2+ advanced breast cancer in BOLERO-1.Basic research in kidney cancer.An update on ethnic differences in drug metabolism and toxicity from anti-cancer drugs.Differences in outcome and toxicity between Asian and caucasian patients with lung cancer treated with systemic therapy.Efficacy and toxicity differences in lung cancer populations in the era of clinical trials globalization: the 'common arm' approach.Race and ethnicity in cancer therapy: what have we learned?Efficacy of motesanib diphosphate in non-small-cell lung cancer.Racial/ethnic differences in drug disposition and response: review of recently approved drugs.MET, HGF, EGFR, and PXN gene copy number in lung cancer using DNA extracts from FFPE archival samples and prognostic significance.Toward Optimum Benefit-Risk and Reduced Access Lag For Cancer Drugs in Asia: A Global Development Framework Guided by Clinical Pharmacology Principles.Efficacy and Safety of First-Line Necitumumab Plus Gemcitabine and Cisplatin Versus Gemcitabine and Cisplatin In East Asian Patients with Stage IV Squamous Non-Small Cell Lung Cancer: A Subgroup Analysis of the Phase 3, Open-Label, Randomized SQUIREDiscordance of Somatic Mutations Between Asian and Caucasian Patient Populations with Gastric Cancer.Brain metastases in non-small cell lung cancer patients on epidermal growth factor receptor tyrosine kinase inhibitors: symptom and economic burden.Bevacizumab plus chemotherapy for patients with advanced pulmonary adenocarcinoma harboring EGFR mutations.Clinicopathological and molecular epidemiological study of lung cancer patients seen at a tertiary care hospital in Northern India.Tumour molecular profiling for deciding therapy-the French initiative.Increased risk of cancer in chronic dialysis patients: a population-based cohort study in Taiwan.A study of therapy targeted EGFR/ALK mutations in Indian patients with lung adenocarcinoma: A clinical and epidemiological study.Management Strategies for Adverse Events Associated With EGFR TKIs in Non-Small Cell Lung Cancer.[A case report of combined small cell lung cancer with EGFR mutation and treatment experience].
P2860
Q24187439-FC0730C1-557E-4E0F-AB0E-9AE579E4F5A9Q26780457-F3D12944-3BA8-431B-AD77-17743E53788AQ28539722-86FC45C3-71DB-4A82-855A-71DD3A0955C5Q30656402-ED691864-17ED-4B79-81F1-A14F29816C93Q33546241-D8E38062-69E5-4239-BB60-506BA3463C6CQ33579631-534F9425-85DD-4B49-9D29-91BEA294F331Q33898749-D666808B-6236-4857-BE8F-78501324EEE1Q33909900-F18A4E1C-4DEC-4DE5-87D8-43FA6B76B97FQ34031225-687DD176-E477-46A2-845C-5AEF234BFE4DQ34041754-AE108EC5-8F50-4102-9A56-BDAA6D566292Q34353920-DB2D9744-EF04-42ED-AF08-34F467FAFC94Q34410885-4F5371AE-6FE0-47BC-B844-96C1CEC2BC5FQ34529055-33CB3B1E-26FC-49A3-A5F0-377DC2FE12C1Q34952066-25CED3D6-D816-45BC-BFEF-FC177B26FE33Q36475104-A1F9B0DA-D34F-4919-9CF4-B12A0E251704Q36876472-0D1D1D88-4B5F-4CD4-8311-A2250EBEC8E3Q37265114-938DCC8C-53D4-44E2-BAE2-D4C1A5CF2230Q37321149-3D6655D6-21DD-4BB2-8F4B-07C8B530EB9AQ37682591-D8E3A23F-50B1-4951-84CF-A93AC1E3C8BAQ37728841-B4CF807B-8936-44C8-950B-309315FCE07DQ37748071-6CEB7BF1-1AC2-48ED-8E39-6762561390ABQ37899447-F8C9A93F-B495-4AE5-A9B2-512B2CDD37AEQ37939200-84991528-153A-4824-9099-79A3927C29EDQ38003669-76309E78-7B1F-446F-9116-447B85C3345AQ38068587-9B2574BC-1B1C-4DAD-9AE1-9B7956D050FCQ38178095-D8BAC644-3839-44FF-BE17-D2F816422296Q38230556-5DD2289F-D616-43F8-A694-BDB0DE2B9AC1Q38351175-981422FB-5F44-4C9C-AF86-66327E063A9EQ38419681-6AD5A988-2AB3-4049-8A16-A7FF0C8725F4Q38719689-A75E4417-2738-4F5A-8052-D684EF729769Q39006417-979AB53F-71CE-41AF-9E5A-743D9488BE7AQ39048329-CB12F6A0-2722-40D6-8A19-444F4203A0EEQ47657310-7A2EFF0C-A782-4E8F-ADD1-CE8BB8DACAAFQ49315676-61D9032C-3115-4130-A1C4-0189097466D1Q49544836-E1A4C17C-7522-414A-B856-82DC62BC10ADQ50929302-69C07855-3DE4-437A-956B-667474FA71F4Q51168825-D6CEFC05-B476-43D6-B782-3FFB27718CE3Q54114458-1669FD09-95FF-40E7-9D0D-A7E7151965FDQ54166640-4BD9EC10-48EF-4584-9668-F86E82DFC4ABQ54343320-823F5D99-FE76-4D6C-B048-AE0BFDE43E2B
P2860
description
2008 nî lūn-bûn
@nan
2008年の論文
@ja
2008年学术文章
@wuu
2008年学术文章
@zh-cn
2008年学术文章
@zh-hans
2008年学术文章
@zh-my
2008年学术文章
@zh-sg
2008年學術文章
@yue
2008年學術文章
@zh
2008年學術文章
@zh-hant
name
Emerging ethnic differences in lung cancer therapy.
@en
Emerging ethnic differences in lung cancer therapy.
@nl
type
label
Emerging ethnic differences in lung cancer therapy.
@en
Emerging ethnic differences in lung cancer therapy.
@nl
prefLabel
Emerging ethnic differences in lung cancer therapy.
@en
Emerging ethnic differences in lung cancer therapy.
@nl
P2093
P2860
P356
P1476
Emerging ethnic differences in lung cancer therapy.
@en
P2093
P2860
P2888
P304
P356
10.1038/SJ.BJC.6604721
P407
P577
2008-11-04T00:00:00Z
2008-12-02T00:00:00Z